Thomas Schmelter

4.0k total citations
45 papers, 1.1k citations indexed

About

Thomas Schmelter is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Thomas Schmelter has authored 45 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Ophthalmology, 12 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Molecular Biology. Recurrent topics in Thomas Schmelter's work include Retinal Diseases and Treatments (13 papers), Retinal Imaging and Analysis (11 papers) and Reproductive Health and Contraception (7 papers). Thomas Schmelter is often cited by papers focused on Retinal Diseases and Treatments (13 papers), Retinal Imaging and Analysis (11 papers) and Reproductive Health and Contraception (7 papers). Thomas Schmelter collaborates with scholars based in Germany, United States and Switzerland. Thomas Schmelter's co-authors include Kristina Gemzell‐Danielsson, K. Rosén, Oliver Zeitz, David S. Boyer, Rupert Sandbrink, Dan Apter, Anita L. Nelson, Robert Vitti, David M. Brown and Alyson J. Berliner and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Thomas Schmelter

44 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Schmelter Germany	17	456	374	246	175	113	45	1.1k
Wei Hong China	17	135 0.3×	223 0.6×	37 0.2×	308 1.8×	150 1.3×	97	931
Haijuan Gu China	15	71 0.2×	46 0.1×	25 0.1×	351 2.0×	148 1.3×	29	866
Ashish Sharma United States	22	1.0k 2.3×	748 2.0×	32 0.1×	355 2.0×	74 0.7×	107	1.6k
Paul Canning United Kingdom	17	225 0.5×	103 0.3×	12 0.0×	330 1.9×	39 0.3×	33	1.0k
Luíz Henrique Gebrim Brazil	15	12 0.0×	36 0.1×	101 0.4×	147 0.8×	251 2.2×	92	735
Jonghyeon Kim United States	17	666 1.5×	310 0.8×	121 0.5×	208 1.2×	95 0.8×	28	1.4k
Mohamed El‐Shinawi Egypt	20	29 0.1×	39 0.1×	41 0.2×	524 3.0×	581 5.1×	68	1.4k
Danny Yu United States	13	17 0.0×	14 0.0×	59 0.2×	400 2.3×	120 1.1×	34	761
Payal D. Shah United States	20	10 0.0×	156 0.4×	25 0.1×	288 1.6×	478 4.2×	72	1.0k
Eriko Sumi Japan	12	15 0.0×	29 0.1×	75 0.3×	214 1.2×	97 0.9×	31	691

Countries citing papers authored by Thomas Schmelter

Since Specialization

Citations

This map shows the geographic impact of Thomas Schmelter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Schmelter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Schmelter more than expected).

Fields of papers citing papers by Thomas Schmelter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Schmelter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Schmelter. The network helps show where Thomas Schmelter may publish in the future.

Co-authorship network of co-authors of Thomas Schmelter

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Schmelter. A scholar is included among the top collaborators of Thomas Schmelter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Schmelter. Thomas Schmelter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rossing, Peter, Justus G. Garweg, Stefan D. Anker, et al.. (2022). Effect of finerenone on the occurrence of vision‐threatening complications in patients with non‐proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants ( ReFineDR / DeFineDR ). Diabetes Obesity and Metabolism. 25(3). 894–898. 14 indexed citations

Miller, Thomas F., Andreas Kaiser, Thomas Schmelter, Jörg Lippert, & Jonathan M. Davis. (2022). Using real-world data in pediatric clinical trials: Lessons learned and future applications in studies of persistent pulmonary hypertension of the newborn. Seminars in Fetal and Neonatal Medicine. 27(4). 101331–101331. 1 indexed citations

Korobelnik, Jean‐François, Michael Larsen, Nicole Eter, et al.. (2021). Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study. American Journal of Ophthalmology. 227. 106–115. 25 indexed citations

Ogura, Yuichiro, Tomohiro Iida, Won Ki Lee, et al.. (2021). Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the Japanese subgroup of the PLANET study. Japanese Journal of Ophthalmology. 65(3). 344–353. 6 indexed citations

Mitchell, Paul, Frank G. Holz, Philip Hykin, et al.. (2020). Comparison of treat-and-extend (T&E) dosing regimens and visual outcomes in the ARIES and ALTAIR studies of intravitreal aflibercept (IVT-AFL) in neovascular age-related macular degeneration (nAMD). Investigative Ophthalmology & Visual Science. 61(7). 4219–4219. 4 indexed citations

Dmitrienko, Alex, Bodo Kirsch, Susanne Lippert, et al.. (2020). A Systematic Approach for Post Hoc Subgroup Analyses With Applications in Clinical Case Studies. Therapeutic Innovation & Regulatory Science. 54(3). 507–518. 2 indexed citations

Joussen, Antonia M., Sebastián Wolf, Peter K. Kaiser, et al.. (2018). The Developing Regorafenib Eye drops for neovascular Age‐related Macular degeneration (DREAM) study: an open‐label phase II trial. British Journal of Clinical Pharmacology. 85(2). 347–355. 41 indexed citations

Joussen, Antonia M., Sebastián Wolf, Peter K. Kaiser, et al.. (2016). A combined phase 2a/b study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). Investigative Ophthalmology & Visual Science. 57(12). 4 indexed citations

Gerlinger, Christoph, Kerstin Gude, Thomas Schmelter, Matthias Schaefers, & Jan Endrikat. (2015). 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes. Climacteric. 18(4). 512–517. 2 indexed citations

10.

Nahum, Gerard G., Andrew M. Kaunitz, K. Rosén, Thomas Schmelter, & R. Lynen. (2015). Ovarian cysts: presence and persistence with use of a 13.5mg levonorgestrel-releasing intrauterine system. Contraception. 91(5). 412–417. 17 indexed citations

11.

Gemzell‐Danielsson, Kristina, Dan Apter, Brian Hauck, et al.. (2015). The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial. PLoS ONE. 10(9). e0135309–e0135309. 39 indexed citations

12.

Heikinheimo, Oskari, Pirjo Inki, Thomas Schmelter, & Kristina Gemzell‐Danielsson. (2014). Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study. Human Reproduction. 29(6). 1182–1188. 22 indexed citations

13.

Nelson, Anita L., Dan Apter, Brian Hauck, et al.. (2013). Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems. Obstetrics and Gynecology. 122(6). 1205–1213. 106 indexed citations

14.

Genazzani, Andrea Riccardo, Thomas Schmelter, Matthias Schaefers, Christoph Gerlinger, & Kerstin Gude. (2013). One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women. Climacteric. 16(4). 490–498. 14 indexed citations

15.

Sutter, Gerd, Thomas Schmelter, Kerstin Gude, et al.. (2013). Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptoms. Menopause The Journal of The North American Menopause Society. 21(3). 236–242. 3 indexed citations

16.

Sørdal, Terje, et al.. (2013). Management of Initial Bleeding or Spotting After Levonorgestrel-Releasing Intrauterine System Placement. Obstetrics and Gynecology. 121(5). 934–941. 12 indexed citations

17.

Archer, David F., Thomas Schmelter, Matthias Schaefers, Christoph Gerlinger, & Kerstin Gude. (2013). A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause The Journal of The North American Menopause Society. 21(3). 227–235. 23 indexed citations

18.

Diana, V., Quan Dong Nguyen, David S. Boyer, et al.. (2012). One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema. Ophthalmology. 119(8). 1658–1665. 305 indexed citations

19.

Divers, Stephen G., Louise Provencher, Shiuh‐Wen Luoh, et al.. (2010). Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Research and Treatment. 123(3). 837–842. 15 indexed citations

20.

Schmelter, Thomas. (2001). Communications out of the Institution - the Balint Group and the Psychiatric Hospital. 2(3). 83–86. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact